Adrenal tumors provide insight into the role of cortisol in NK cell activity
Greenstein et al. • 2021 • Endocr Relat Cancer . 2021 Jun 29;28(8):583-592. doi: 10.1530/ERC-21-0048.
© 2024 Corcept Therapeutics, Incorporated
Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects: A Proof-of-Concept Study
Hunt et al • 2021 • Journal of Clinical Psychopharmacology: August 6, 2021
Prevalence of Hypercortisolism in Patients With Adrenal Adenoma(s) and Type 2 Diabetes Mellitus: Findings From an Electronic Medical Records (EMR) Search
Isaac Sachmechi, MD, FACE, FACP; Sanna Salam; Muhammad Umair, MD; Kathleen Wade Tarnowski, MSc • 2021 •
Use of Mifepristone in a Hypercortisolemic Patient With End-Stage Renal Disease on Hemodialysis
Albert W. Coo, MD, FACE; Rebecca Ray, FNP-C • 2021 •
Suppression of Tumor Immune Activity in Adrenocortical Carcinoma with Excess Glucocorticoid
Greenstein et al. • 2020 • AACR Annual Meeting 2020
Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol.
Greenstein et al. • 2020 • Citation: J Clin Oncol 38: 2020 (suppl; abstract #: 3091)
Reversal of Antipsychotic-Induced Weight Gain in Rats with Miricorilant, a Selective Glucocorticoid Receptor (GR) Modulator
Lee et al. • 2020 • 2020 Annual Meeting – American Psychiatric Association (APA)
GRADIENT: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of a Selective Glucocorticoid Receptor Modulator, Relacorilant, in Patients With Autonomous Cortisol Secretion Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia
Auchus et al. • 2020 • J Endocr Soc. Vol 4, Issue Suppl 1 April-May
Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A Prospective Study of 384 Newly Diagnosed Patients
Steffensen et al • 2019 • Horm Metab Res.